536:
IL-4RII. The IL-4/IL-4RĪ± complex, however, can also bind to a different secondary chain, the IL-2RĪ³c, forming the IL-4 receptor type I (IL-4RI). In non-hematopoietic cells, IL-2RĪ³c is poorly expressed; on the other hand, IL-13RĪ±1 is poorly expressed in lymphocytes but abundantly in all non-hematopoietic cells; myeloid cells express both of them to a certain degree. This different distribution of secondary chains accounts for the difference in distribution of completed receptors, with being IL-4RI prevalently expressed in lymphocyte, and IL-4RII prevalently in non-hematopoietic cells. Consequently, only IL-4, through IL-4R1, is able to modulate the function of lymphocytes inducing Th2 polarisation and B cells IgG1/IgE class switching, while IL-13 is mainly acting on myeloid cells and non-hematopoietic cells, having strong effects on mucus production, smooth muscle contraction, epithelium permeabilisation (e.g. allergic asthma). After the complete assemblage, the conformational changes in IL-4RI or IL-4RII tails leads to the intracellular signaling, starting with the auto and cross-phosphorylation of associated Jak kinases (Jak3 for IL-2RĪ³c, Jak1 for IL-4RĪ±, Jak2 and Tyk2 for IL-13RĪ±1), and followed by phosphorylation of intracellular domains of IL-4RĪ± in critical Y residues which are therefore activated to form the docking sites for downstream signalling molecules endowed with SH domains. While the docking sites in IL-4R1 (and consequently IL-4) are able to efficiently activate both STAT6 and IRS2 signalling molecules, IL-4RII (and consequently IL-13) only activates effectively STAT6. Activated STAT6 molecules form dimers which translocate to the nucleus to bind responsive elements (e.g. CD23 promoter in B cells, arginase1 enhancer in macrophages ) The binding affinity of IL-4 for IL-4RĪ± is much higher than IL-13 for the IL-13RĪ±1, hence IL-4 would out-compete IL-13 for receptor availability within IL4R2 at parity of concentration.
545:
presents an extraordinary affinity to IL-13, but does not form complexes with any secondary chain. Because of the apparent lack of signaling domain and the short tail, it has been initially thought not to have any signaling activity, and regarded as ādecoyā receptor, that is its function would just consist in competing for IL-13 binding and neutralizing his effect. Indeed, it has been shown that IL-13RĪ±2 blocks IL-13 driven STAT6 signalling by binding IL-13 with high affinity, however a partial block is also extending to IL-4 driven STAT6 signalling, presumably due to the cytoplasmic domain interfering with the assembling of IL-4/IL-4RĪ± with a secondary chain. However, increasing evidences are accumulating that IL-13RĪ±2 is more than a ādecoyā. IL-13 signalling through IL-13RĪ±2 and AP1-driven TGF-Ī² production has been initially reported in monocytes and then confirmed in mouse models. According these studies, IL-13, through the over-expression (TNF-Ī± induced) of IL-13RĪ±2 would be able to activate AP-1 signalling and production of TGF-Ī², driving pro-fibrotic effects. Some recent works is evidencing how a wide range of signals can be actually activated by this receptor (e.g. WNT/Ī²-Catenin, MAPK/ERK, AKT/PKB, Src/FAK, PIP3K ) in normal or pathologic environments. How IL-13RĪ±2 might overcome the limitation of a 17 aminoacids short tail lacking any signalling motif, it is not clear yet but it has been shown that, at least in some cases, the association with other receptors or signalling adaptors can do the trick.
535:
IL-13 uses the IL-4 receptor type II (IL-4RII), a complex formed by an IL-4RĪ± chain and an IL-13RĪ±1 chain. Initially, the ligand (IL-4 or IL-13) binds to the IL-4RĪ± chain and IL-13RĪ±1 respectively; thereafter, a secondary chain (IL-13RĪ±1 and IL-4RĪ± respectively) will also bind, forming the complete
526:
Interleukin 13 (IL-13) is an effector cytokine partially sharing the signaling pathways with IL-4 due to the utilization of a common receptor system (IL-4 receptor type II). A āprivateā receptor system, binding specifically IL-13 with high affinity, seems to use different signalling pathways and is
544:
Besides IL-13RĪ±1 chain (which work in conjunction with the IL-4RĪ±, IL-13 can bind with much higher affinity to IL-13RĪ±2. IL-13RĪ±2 presents 35% homology with IL-13RĪ±1 and it is expressed mostly in structural cell (but also has been identified in fibroblasts and, only in mice, in soluble form). It
517:
gene. This binds IL-13 with very high affinity (and can therefore sequester it) but does not allow IL-4 binding. It acts as a negative regulator of both IL-13 and IL-4, however the mechanism of this is still undetermined.
486:, respectively. These two genes encode the proteins IL-13RĪ±1 and IL-4RĪ±. These form a dimer with IL-13 binding to the IL-13RĪ±1 chain and IL-4RĪ± stabilises this interaction. This IL-13 receptor can also instigate
1235:
Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A (January 2006). "IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis".
2479:
2054:
1380:
He CH, Lee CG, Dela Cruz CS, Lee CM, Zhou Y, Ahangari F, Ma B, Herzog EL, Rosenberg SA, Li Y, Nour AM, Parikh CR, Schmidt I, Modis Y, Cantley L, Elias JA (August 2013).
1050:
Keegan AD, Conrad DH. The murine lymphocyte receptor for IgE. V. Biosynthesis, transport, and maturation of the B cell Fc epsilon receptor. J Immunol (1987) 139:1199ā205
2177:
2472:
350:
201:
52:
1464:
1854:
2465:
2425:
2143:
2139:
2122:
3677:
2944:
2256:
2231:
2095:
562:
Murata T, Obiri NI, Puri RK (March 1998). "Structure of and signal transduction through interleukin-4 and interleukin-13 receptors (review)".
3747:
3681:
3667:
3627:
2260:
2235:
2086:
3742:
3696:
2413:
2112:
2047:
527:
increasingly being studied for its potential as a novel prognostic factor, biomarker or therapeutic target in different types of cancer.
2107:
374:
225:
76:
3752:
3601:
2549:
1331:"IL13 Receptor Ī±2 Signaling Requires a Scaffold Protein, FAM120A, to Activate the FAK and PI3K Pathways in Colon Cancer Metastasis"
1986:
1691:
1683:
1457:
362:
213:
64:
2334:
1632:
1155:"Endogenously expressed IL-13RĪ±2 attenuates IL-13-mediated responses but does not activate signaling in human lung fibroblasts"
355:
206:
57:
2329:
2277:
1668:
3562:
3541:
1581:
1543:
1538:
1586:
2298:
2294:
1450:
1999:
727:
Suzuki A, Leland P, Joshi BH, Puri RK (September 2015). "Targeting of IL-4 and IL-13 receptors for cancer therapy".
2314:
1930:
1486:
1278:
Brunner SM, Schiechl G, Kesselring R, Martin M, Balam S, Schlitt HJ, Geissler EK, Fichtner-Feigl S (October 2013).
764:"IL-13 receptor Ī±2 is a negative prognostic factor in human lung cancer and stimulates lung cancer growth in mice"
2290:
2214:
1913:
1699:
813:"Interleukin-13 receptor Ī±2 is associated with poor prognosis in patients with gastric cancer after gastrectomy"
2444:
2408:
1939:
1436:
471:
3520:
3480:
3459:
3403:
3371:
3330:
3288:
3242:
3161:
3135:
3038:
3012:
2986:
2640:
2363:
2341:
2265:
2252:
2239:
2227:
2195:
2182:
2172:
2148:
2135:
2091:
2082:
2009:
1973:
1568:
3095:
2955:
2935:
2914:
2833:
2772:
2716:
2670:
2594:
2499:
2400:
2324:
2077:
2043:
2034:
2004:
1995:
1978:
1576:
1496:
367:
218:
69:
2102:
420:
2605:
1432:
3717:
3500:
2488:
2222:
2130:
2072:
2029:
1956:
915:
271:
122:
2630:
3491:
3049:
2844:
2620:
2514:
2439:
2434:
2272:
506:. Phosphorylated STAT6 dimerises and acts as a transcription factor activating many genes, such as
3361:
3356:
1329:
BartolomĆ© RA, GarcĆa-Palmero I, Torres S, LĆ³pez-Lucendo M, Balyasnikova IV, Casal JI (June 2015).
3341:
3253:
3232:
2681:
2615:
2574:
2518:
2491:
2429:
2200:
1948:
1481:
1260:
598:
424:
3222:
3090:
2997:
2976:
2727:
2696:
2691:
2635:
2554:
3268:
2701:
2529:
2524:
1153:
Chandriani S, DePianto DJ, N'Diaye EN, Abbas AR, Jackman J, Bevers J, et al. (July 2014).
902:
Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD (December 1998).
2874:
2859:
2823:
2793:
2539:
1473:
1411:
1362:
1311:
1252:
1217:
1176:
1135:
1083:
1033:
984:
933:
884:
842:
793:
744:
709:
660:
618:
579:
953:"Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes"
3712:
2388:
2191:
2064:
1905:
1897:
1798:
1790:
1782:
1774:
1401:
1393:
1352:
1342:
1301:
1291:
1244:
1207:
1166:
1125:
1117:
1073:
1023:
1015:
974:
964:
923:
876:
832:
824:
783:
775:
736:
699:
691:
652:
610:
571:
415:
266:
117:
3188:
3184:
3180:
275:
3504:
1814:
1194:
Zheng T, Liu W, Oh SY, Zhu Z, Hu B, Homer RJ, Cohn L, Grusby MJ, Elias JA (January 2008).
1004:"Type I IL-4Rs selectively activate IRS-2 to induce target gene expression in macrophages"
499:
444:
295:
146:
126:
919:
3702:
3692:
3687:
3673:
3659:
3649:
3644:
3591:
3573:
3552:
3531:
3510:
3496:
3470:
3414:
3382:
3346:
3309:
3304:
3299:
3263:
3258:
3172:
3151:
3105:
3054:
3023:
3002:
2737:
2706:
1715:
1406:
1381:
1306:
1279:
1196:"IL-13 receptor alpha2 selectively inhibits IL-13-induced responses in the murine lung"
1130:
1105:
1028:
1003:
1002:
Heller NM, Qi X, Junttila IS, Shirey KA, Vogel SN, Paul WE, Keegan AD (December 2008).
979:
952:
837:
812:
788:
763:
704:
679:
638:"Interleukin-13 as an important cytokine: A review on its roles in some human diseases"
475:
3736:
3444:
3100:
2966:
2925:
2849:
2783:
2732:
2686:
2625:
2510:
2167:
1961:
880:
487:
1264:
811:
Lin C, Liu H, Zhang H, He H, Li H, Shen Z, Qin J, Qin X, Xu J, Sun Y (August 2016).
3618:
3439:
3125:
3120:
3115:
2864:
2803:
2762:
2355:
1723:
495:
491:
2457:
1382:"Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor Ī±2"
1347:
1330:
928:
903:
637:
601:(1998). "Interleukin-4 and interleukin-13: their similarities and discrepancies".
1397:
1078:
1061:
678:
Thaci B, Brown CE, Binello E, Werbaneth K, Sampath P, Sengupta S (October 2014).
391:
242:
93:
3449:
3429:
3392:
3227:
3217:
3069:
3064:
2899:
2869:
2808:
2650:
2610:
2569:
2564:
1548:
1523:
454:
305:
156:
1212:
1195:
1121:
1060:
Pauleau AL, Rutschman R, Lang R, Pernis A, Watowich SS, Murray PJ (June 2004).
740:
680:"Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy"
3434:
3424:
3319:
3212:
3207:
3028:
2889:
2879:
2813:
2747:
2660:
2655:
2584:
1019:
828:
614:
398:
249:
100:
1171:
1154:
969:
779:
513:
There is also another receptor that can bind IL-13: IL-13RĪ±2 encoded by the
2904:
2894:
2884:
2757:
1838:
1830:
1822:
695:
656:
1415:
1366:
1315:
1296:
1280:"IL-13 signaling via IL-13RĪ±2 triggers TGF-Ī²1-dependent allograft fibrosis"
1256:
1221:
1180:
1139:
1087:
1037:
988:
888:
846:
797:
748:
713:
664:
937:
622:
583:
2544:
1878:
1870:
1862:
1846:
575:
403:
254:
105:
1357:
1062:"Enhancer-mediated control of macrophage-specific arginase I expression"
3663:
3146:
2247:
2243:
1990:
514:
507:
479:
186:
171:
37:
22:
3278:
2383:
2378:
2373:
2368:
2345:
2285:
2281:
2021:
1654:
1442:
386:
237:
88:
864:
1248:
3585:
3581:
3577:
3196:
3192:
3176:
2418:
2038:
1969:
1965:
1755:
1707:
1649:
1613:
1608:
1603:
1598:
1593:
1558:
1518:
1508:
636:
Seyfizadeh N, Seyfizadeh N, Gharibi T, Babaloo Z (December 2015).
503:
1806:
1747:
1739:
1731:
1642:
1553:
1533:
1528:
1513:
1504:
865:"The IL-4 receptor: signaling mechanisms and biologic functions"
483:
379:
335:
320:
230:
81:
2461:
1446:
3653:
490:
signalling. In both cases this occurs via activation of the
863:
Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE (1999).
494:(JAK)/Signal Transducer and Activator of Transcription (
904:"Interleukin-13: central mediator of allergic asthma"
1106:"Commentary: IL-4 and IL-13 receptors and signaling"
3637:
3617:
3610:
3561:
3540:
3519:
3479:
3458:
3402:
3370:
3329:
3287:
3241:
3160:
3134:
3078:
3037:
3011:
2985:
2954:
2934:
2913:
2832:
2771:
2715:
2669:
2593:
2498:
2399:
2354:
2313:
2213:
2159:
2121:
2063:
2020:
1947:
1938:
1929:
1890:
1767:
1676:
1667:
1622:
1567:
1495:
1480:
450:
440:
435:
414:
409:
397:
385:
373:
361:
349:
341:
331:
326:
319:
301:
291:
286:
265:
260:
248:
236:
224:
212:
200:
192:
182:
177:
170:
152:
142:
137:
116:
111:
99:
87:
75:
63:
51:
43:
33:
28:
21:
1099:
1097:
762:Xie M, Wu XJ, Zhang JJ, He CS (October 2015).
2473:
1458:
645:Acta Microbiologica et Immunologica Hungarica
8:
858:
856:
564:International Journal of Molecular Medicine
3614:
2480:
2466:
2458:
1944:
1935:
1673:
1492:
1465:
1451:
1443:
1104:McCormick SM, Heller NM (September 2015).
478:. It consists of two subunits, encoded by
432:
283:
134:
1435:at the U.S. National Library of Medicine
1405:
1356:
1346:
1305:
1295:
1211:
1170:
1129:
1077:
1027:
978:
968:
927:
836:
787:
703:
16:Cell surface receptors for interleukin-13
3645:Interleukin 14 (taxilin alpha, HMW-BCGF)
554:
2943:See CXCR1 (IL-8RĪ±) and CXCR2 (IL-8RĪ²)
316:
167:
18:
7:
603:International Reviews of Immunology
531:The āsharedā IL-4 / IL-13 receptor
14:
881:10.1146/annurev.immunol.17.1.701
172:interleukin 13 receptor, alpha 2
23:interleukin 13 receptor, alpha 1
3471:Interleukin 27 (interleukin 30)
1:
1348:10.1158/0008-5472.CAN-14-3650
929:10.1126/science.282.5397.2258
3748:Genes on human chromosome 16
1398:10.1016/j.celrep.2013.07.032
1079:10.4049/jimmunol.172.12.7565
540:The āprivateā IL-13 receptor
3743:Genes on human chromosome X
2821:Antisense oligonucleotides:
869:Annual Review of Immunology
3769:
1213:10.4049/jimmunol.180.1.522
1122:10.1016/j.cyto.2015.05.023
741:10.1016/j.cyto.2015.05.026
3753:Type I cytokine receptors
1433:Receptors,+Interleukin-13
1020:10.1126/scisignal.1164795
829:10.18632/oncotarget.10297
615:10.3109/08830189809084486
431:
282:
133:
1437:Medical Subject Headings
1284:Transplantation Research
1172:10.4049/jimmunol.1301761
970:10.3389/fimmu.2018.00888
780:10.18632/oncotarget.5361
498:) pathway, resulting in
472:type I cytokine receptor
3511:Interleukin-29 (IFN-Ī»1)
2656:Daclizumab (dacliximab)
2641:Tucotuzumab celmoleukin
957:Frontiers in Immunology
657:10.1556/030.62.2015.4.2
468:interleukin-13 receptor
196:IL-13R, IL13BP, CD213a2
3492:Interferon Ī»4 (IFN-Ī»4)
2585:Rilonacept (IL-1 Trap)
2401:Enzyme-linked receptor
1297:10.1186/2047-1440-2-16
321:interleukin 4 receptor
3415:Interleukin 23 (SGRF)
3096:Cintredekin besudotox
3024:Interleukin 11 (AGIF)
3003:Interleukin 10 (CSIF)
2223:Interleukin receptors
2131:Interleukin receptors
2073:Interleukin receptors
2030:Interleukin receptors
1957:Interleukin receptors
1200:Journal of Immunology
1159:Journal of Immunology
1066:Journal of Immunology
696:10.1093/neuonc/nou045
47:IL-13Ra, NR4, CD213a1
2489:Interleukin receptor
2273:Interferon receptors
951:Junttila IS (2018).
576:10.3892/ijmm.1.3.551
2621:Denileukin diftitox
920:1998Sci...282.2258W
823:(31): 49281ā49288.
3193:E (interleukin 25)
1482:Chemokine receptor
1474:Cytokine receptors
3730:
3729:
3726:
3725:
3695:(signals through
3676:(signals through
3662:(signals through
3652:(signals through
3276:Binding proteins:
2606:Adargileukin alfa
2455:
2454:
2309:
2308:
2209:
2208:
1925:
1924:
1663:
1662:
1008:Science Signaling
914:(5397): 2258ā61.
464:
463:
460:
459:
315:
314:
311:
310:
166:
165:
162:
161:
3760:
3718:Efineptakin alfa
3713:Efavaleukin alfa
3615:
2582:Decoy receptors:
2482:
2475:
2468:
2459:
2192:hormone receptor
1945:
1936:
1674:
1493:
1467:
1460:
1453:
1444:
1420:
1419:
1409:
1377:
1371:
1370:
1360:
1350:
1326:
1320:
1319:
1309:
1299:
1275:
1269:
1268:
1232:
1226:
1225:
1215:
1191:
1185:
1184:
1174:
1150:
1144:
1143:
1133:
1101:
1092:
1091:
1081:
1057:
1051:
1048:
1042:
1041:
1031:
999:
993:
992:
982:
972:
948:
942:
941:
931:
899:
893:
892:
860:
851:
850:
840:
808:
802:
801:
791:
774:(32): 32902ā13.
759:
753:
752:
724:
718:
717:
707:
675:
669:
668:
642:
633:
627:
626:
594:
588:
587:
559:
433:
317:
284:
168:
135:
19:
3768:
3767:
3763:
3762:
3761:
3759:
3758:
3757:
3733:
3732:
3731:
3722:
3633:
3606:
3557:
3536:
3515:
3475:
3454:
3398:
3395:(against IL-22)
3366:
3325:
3322:(against IL-20)
3283:
3237:
3156:
3130:
3074:
3033:
3007:
2981:
2950:
2930:
2909:
2828:
2767:
2711:
2665:
2589:
2494:
2486:
2456:
2451:
2395:
2350:
2305:
2205:
2155:
2117:
2059:
2016:
1921:
1886:
1815:Osteoprotegerin
1763:
1659:
1618:
1563:
1484:
1476:
1471:
1429:
1424:
1423:
1379:
1378:
1374:
1341:(12): 2434ā44.
1335:Cancer Research
1328:
1327:
1323:
1277:
1276:
1272:
1237:Nature Medicine
1234:
1233:
1229:
1193:
1192:
1188:
1152:
1151:
1147:
1103:
1102:
1095:
1072:(12): 7565ā73.
1059:
1058:
1054:
1049:
1045:
1001:
1000:
996:
950:
949:
945:
901:
900:
896:
862:
861:
854:
810:
809:
805:
761:
760:
756:
726:
725:
721:
690:(10): 1304ā12.
677:
676:
672:
640:
635:
634:
630:
596:
595:
591:
561:
560:
556:
551:
542:
533:
524:
500:phosphorylation
17:
12:
11:
5:
3766:
3764:
3756:
3755:
3750:
3745:
3735:
3734:
3728:
3727:
3724:
3723:
3721:
3720:
3715:
3706:
3705:
3703:Interleukin 35
3700:
3693:Interleukin 34
3690:
3688:Interleukin 32
3685:
3674:Interleukin 26
3671:
3660:Interleukin 24
3657:
3650:Interleukin 16
3647:
3641:
3639:
3635:
3634:
3632:
3631:
3623:
3621:
3612:
3608:
3607:
3605:
3604:
3595:
3594:
3592:Interleukin 38
3589:
3574:Interleukin 36
3567:
3565:
3559:
3558:
3556:
3555:
3553:Interleukin 33
3546:
3544:
3538:
3537:
3535:
3534:
3532:Interleukin 31
3525:
3523:
3517:
3516:
3514:
3513:
3508:
3497:Interleukin 28
3494:
3485:
3483:
3477:
3476:
3474:
3473:
3464:
3462:
3456:
3455:
3453:
3452:
3447:
3442:
3437:
3432:
3427:
3418:
3417:
3408:
3406:
3400:
3399:
3397:
3396:
3386:
3385:
3383:Interleukin 22
3376:
3374:
3368:
3367:
3365:
3364:
3359:
3350:
3349:
3347:Interleukin 21
3344:
3335:
3333:
3327:
3326:
3324:
3323:
3313:
3312:
3310:Interleukin 24
3307:
3305:Interleukin 20
3302:
3300:Interleukin 19
3293:
3291:
3285:
3284:
3282:
3281:
3272:
3271:
3266:
3264:Interleukin 37
3261:
3259:Interleukin 18
3256:
3247:
3245:
3239:
3238:
3236:
3235:
3230:
3225:
3220:
3215:
3210:
3201:
3200:
3173:Interleukin 17
3166:
3164:
3158:
3157:
3155:
3154:
3152:Interleukin 15
3149:
3140:
3138:
3132:
3131:
3129:
3128:
3123:
3118:
3109:
3108:
3106:Interleukin 13
3103:
3098:
3093:
3084:
3082:
3076:
3075:
3073:
3072:
3067:
3058:
3057:
3055:Interleukin 12
3052:
3043:
3041:
3035:
3034:
3032:
3031:
3026:
3017:
3015:
3009:
3008:
3006:
3005:
3000:
2991:
2989:
2983:
2982:
2980:
2979:
2970:
2969:
2960:
2958:
2952:
2951:
2949:
2948:
2940:
2938:
2932:
2931:
2929:
2928:
2919:
2917:
2911:
2910:
2908:
2907:
2902:
2897:
2892:
2887:
2882:
2877:
2872:
2867:
2862:
2853:
2852:
2847:
2838:
2836:
2830:
2829:
2827:
2826:
2817:
2816:
2811:
2806:
2797:
2796:
2787:
2786:
2777:
2775:
2769:
2768:
2766:
2765:
2760:
2751:
2750:
2741:
2740:
2738:Interleukin 13
2735:
2730:
2721:
2719:
2713:
2712:
2710:
2709:
2707:Promegapoietin
2704:
2699:
2694:
2689:
2684:
2675:
2673:
2667:
2666:
2664:
2663:
2658:
2653:
2644:
2643:
2638:
2633:
2631:Pegaldesleukin
2628:
2623:
2618:
2613:
2608:
2599:
2597:
2591:
2590:
2588:
2587:
2578:
2577:
2572:
2567:
2558:
2557:
2552:
2547:
2542:
2533:
2532:
2527:
2522:
2504:
2502:
2496:
2495:
2487:
2485:
2484:
2477:
2470:
2462:
2453:
2452:
2450:
2449:
2448:
2447:
2442:
2437:
2423:
2422:
2421:
2416:
2405:
2403:
2397:
2396:
2394:
2393:
2392:
2391:
2386:
2381:
2376:
2371:
2360:
2358:
2352:
2351:
2349:
2348:
2339:
2338:
2337:
2332:
2322:
2319:
2317:
2315:Ig superfamily
2311:
2310:
2307:
2306:
2304:
2303:
2302:
2301:
2288:
2270:
2269:
2268:
2263:
2250:
2219:
2217:
2211:
2210:
2207:
2206:
2204:
2203:
2198:
2188:
2187:
2186:
2185:
2183:Thrombopoietin
2180:
2175:
2163:
2161:
2157:
2156:
2154:
2153:
2152:
2151:
2146:
2127:
2125:
2119:
2118:
2116:
2115:
2110:
2105:
2100:
2099:
2098:
2089:
2080:
2069:
2067:
2061:
2060:
2058:
2057:
2052:
2051:
2050:
2041:
2026:
2024:
2018:
2017:
2015:
2014:
2013:
2012:
2007:
2002:
1993:
1976:
1953:
1951:
1942:
1933:
1927:
1926:
1923:
1922:
1920:
1919:
1911:
1903:
1894:
1892:
1888:
1887:
1885:
1884:
1876:
1868:
1860:
1852:
1844:
1836:
1828:
1820:
1812:
1804:
1796:
1788:
1780:
1771:
1769:
1765:
1764:
1762:
1761:
1753:
1745:
1737:
1729:
1721:
1713:
1705:
1697:
1689:
1680:
1678:
1671:
1665:
1664:
1661:
1660:
1658:
1657:
1652:
1647:
1646:
1645:
1637:
1636:
1635:
1626:
1624:
1620:
1619:
1617:
1616:
1611:
1606:
1601:
1596:
1591:
1590:
1589:
1584:
1573:
1571:
1565:
1564:
1562:
1561:
1556:
1551:
1546:
1541:
1536:
1531:
1526:
1521:
1516:
1511:
1501:
1499:
1490:
1478:
1477:
1472:
1470:
1469:
1462:
1455:
1447:
1441:
1440:
1428:
1427:External links
1425:
1422:
1421:
1372:
1321:
1270:
1249:10.1038/nm1332
1227:
1186:
1145:
1093:
1052:
1043:
994:
943:
894:
852:
803:
754:
719:
684:Neuro-Oncology
670:
628:
589:
553:
552:
550:
547:
541:
538:
532:
529:
523:
520:
476:Interleukin-13
462:
461:
458:
457:
452:
448:
447:
442:
438:
437:
429:
428:
418:
412:
411:
407:
406:
401:
395:
394:
389:
383:
382:
377:
371:
370:
365:
359:
358:
353:
347:
346:
343:
339:
338:
333:
329:
328:
324:
323:
313:
312:
309:
308:
303:
299:
298:
293:
289:
288:
280:
279:
269:
263:
262:
258:
257:
252:
246:
245:
240:
234:
233:
228:
222:
221:
216:
210:
209:
204:
198:
197:
194:
190:
189:
184:
180:
179:
175:
174:
164:
163:
160:
159:
154:
150:
149:
144:
140:
139:
131:
130:
120:
114:
113:
109:
108:
103:
97:
96:
91:
85:
84:
79:
73:
72:
67:
61:
60:
55:
49:
48:
45:
41:
40:
35:
31:
30:
26:
25:
15:
13:
10:
9:
6:
4:
3:
2:
3765:
3754:
3751:
3749:
3746:
3744:
3741:
3740:
3738:
3719:
3716:
3714:
3711:
3708:
3707:
3704:
3701:
3698:
3694:
3691:
3689:
3686:
3683:
3679:
3675:
3672:
3669:
3665:
3661:
3658:
3655:
3651:
3648:
3646:
3643:
3642:
3640:
3636:
3629:
3625:
3624:
3622:
3620:
3616:
3613:
3609:
3603:
3600:
3597:
3596:
3593:
3590:
3587:
3583:
3579:
3575:
3572:
3569:
3568:
3566:
3564:
3560:
3554:
3551:
3548:
3547:
3545:
3543:
3539:
3533:
3530:
3527:
3526:
3524:
3522:
3518:
3512:
3509:
3506:
3502:
3498:
3495:
3493:
3490:
3487:
3486:
3484:
3482:
3478:
3472:
3469:
3466:
3465:
3463:
3461:
3457:
3451:
3448:
3446:
3445:Tildrakizumab
3443:
3441:
3438:
3436:
3433:
3431:
3428:
3426:
3423:
3420:
3419:
3416:
3413:
3410:
3409:
3407:
3405:
3401:
3394:
3391:
3388:
3387:
3384:
3381:
3378:
3377:
3375:
3373:
3369:
3363:
3360:
3358:
3355:
3352:
3351:
3348:
3345:
3343:
3340:
3337:
3336:
3334:
3332:
3328:
3321:
3318:
3315:
3314:
3311:
3308:
3306:
3303:
3301:
3298:
3295:
3294:
3292:
3290:
3286:
3280:
3277:
3274:
3273:
3270:
3267:
3265:
3262:
3260:
3257:
3255:
3252:
3249:
3248:
3246:
3244:
3240:
3234:
3231:
3229:
3226:
3224:
3221:
3219:
3216:
3214:
3211:
3209:
3206:
3203:
3202:
3198:
3194:
3190:
3186:
3182:
3178:
3174:
3171:
3168:
3167:
3165:
3163:
3159:
3153:
3150:
3148:
3145:
3142:
3141:
3139:
3137:
3133:
3127:
3124:
3122:
3119:
3117:
3114:
3111:
3110:
3107:
3104:
3102:
3101:Interleukin 4
3099:
3097:
3094:
3092:
3089:
3086:
3085:
3083:
3081:
3077:
3071:
3068:
3066:
3063:
3060:
3059:
3056:
3053:
3051:
3050:Edodekin alfa
3048:
3045:
3044:
3042:
3040:
3036:
3030:
3027:
3025:
3022:
3019:
3018:
3016:
3014:
3010:
3004:
3001:
2999:
2996:
2993:
2992:
2990:
2988:
2984:
2978:
2975:
2972:
2971:
2968:
2967:Interleukin 9
2965:
2962:
2961:
2959:
2957:
2953:
2946:
2942:
2941:
2939:
2937:
2933:
2927:
2926:Interleukin 7
2924:
2921:
2920:
2918:
2916:
2912:
2906:
2903:
2901:
2898:
2896:
2893:
2891:
2888:
2886:
2883:
2881:
2878:
2876:
2873:
2871:
2868:
2866:
2863:
2861:
2858:
2855:
2854:
2851:
2850:Interleukin 6
2848:
2846:
2845:Atexakin alfa
2843:
2840:
2839:
2837:
2835:
2831:
2825:
2822:
2819:
2818:
2815:
2812:
2810:
2807:
2805:
2802:
2799:
2798:
2795:
2792:
2789:
2788:
2785:
2784:Interleukin 5
2782:
2779:
2778:
2776:
2774:
2770:
2764:
2761:
2759:
2756:
2753:
2752:
2749:
2746:
2743:
2742:
2739:
2736:
2734:
2733:Interleukin 4
2731:
2729:
2726:
2723:
2722:
2720:
2718:
2714:
2708:
2705:
2703:
2700:
2698:
2695:
2693:
2690:
2688:
2687:Interleukin 3
2685:
2683:
2680:
2677:
2676:
2674:
2672:
2668:
2662:
2659:
2657:
2654:
2652:
2649:
2646:
2645:
2642:
2639:
2637:
2634:
2632:
2629:
2627:
2626:Interleukin 2
2624:
2622:
2619:
2617:
2614:
2612:
2609:
2607:
2604:
2601:
2600:
2598:
2596:
2592:
2586:
2583:
2580:
2579:
2576:
2573:
2571:
2568:
2566:
2563:
2560:
2559:
2556:
2553:
2551:
2548:
2546:
2543:
2541:
2538:
2535:
2534:
2531:
2528:
2526:
2523:
2520:
2516:
2512:
2511:Interleukin 1
2509:
2506:
2505:
2503:
2501:
2497:
2493:
2490:
2483:
2478:
2476:
2471:
2469:
2464:
2463:
2460:
2446:
2443:
2441:
2438:
2436:
2433:
2432:
2431:
2427:
2424:
2420:
2417:
2415:
2412:
2411:
2410:
2407:
2406:
2404:
2402:
2398:
2390:
2387:
2385:
2382:
2380:
2377:
2375:
2372:
2370:
2367:
2366:
2365:
2362:
2361:
2359:
2357:
2353:
2347:
2343:
2340:
2336:
2333:
2331:
2328:
2327:
2326:
2323:
2321:
2320:
2318:
2316:
2312:
2300:
2296:
2292:
2289:
2287:
2283:
2279:
2276:
2275:
2274:
2271:
2267:
2264:
2262:
2258:
2254:
2251:
2249:
2245:
2241:
2237:
2233:
2229:
2226:
2225:
2224:
2221:
2220:
2218:
2216:
2212:
2202:
2199:
2197:
2193:
2190:
2189:
2184:
2181:
2179:
2176:
2174:
2171:
2170:
2169:
2168:CSF receptors
2165:
2164:
2162:
2158:
2150:
2147:
2145:
2141:
2137:
2134:
2133:
2132:
2129:
2128:
2126:
2124:
2120:
2114:
2111:
2109:
2106:
2104:
2101:
2097:
2093:
2090:
2088:
2084:
2081:
2079:
2076:
2075:
2074:
2071:
2070:
2068:
2066:
2062:
2056:
2053:
2049:
2045:
2042:
2040:
2036:
2033:
2032:
2031:
2028:
2027:
2025:
2023:
2019:
2011:
2008:
2006:
2003:
2001:
1997:
1994:
1992:
1988:
1984:
1980:
1977:
1975:
1971:
1967:
1963:
1960:
1959:
1958:
1955:
1954:
1952:
1950:
1946:
1943:
1941:
1937:
1934:
1932:
1928:
1918:
1915:
1912:
1910:
1907:
1904:
1902:
1899:
1896:
1895:
1893:
1889:
1883:
1880:
1877:
1875:
1872:
1869:
1867:
1864:
1861:
1859:
1856:
1853:
1851:
1848:
1845:
1843:
1840:
1837:
1835:
1832:
1829:
1827:
1824:
1821:
1819:
1816:
1813:
1811:
1808:
1805:
1803:
1800:
1797:
1795:
1792:
1789:
1787:
1784:
1781:
1779:
1776:
1773:
1772:
1770:
1766:
1760:
1757:
1754:
1752:
1749:
1746:
1744:
1741:
1738:
1736:
1733:
1730:
1728:
1725:
1722:
1720:
1717:
1714:
1712:
1709:
1706:
1704:
1701:
1698:
1696:
1693:
1690:
1688:
1685:
1682:
1681:
1679:
1675:
1672:
1670:
1666:
1656:
1653:
1651:
1648:
1644:
1641:
1640:
1638:
1634:
1631:
1630:
1628:
1627:
1625:
1621:
1615:
1612:
1610:
1607:
1605:
1602:
1600:
1597:
1595:
1592:
1588:
1585:
1583:
1580:
1579:
1578:
1575:
1574:
1572:
1570:
1566:
1560:
1557:
1555:
1552:
1550:
1547:
1545:
1542:
1540:
1537:
1535:
1532:
1530:
1527:
1525:
1522:
1520:
1517:
1515:
1512:
1510:
1506:
1503:
1502:
1500:
1498:
1494:
1491:
1488:
1483:
1479:
1475:
1468:
1463:
1461:
1456:
1454:
1449:
1448:
1445:
1438:
1434:
1431:
1430:
1426:
1417:
1413:
1408:
1403:
1399:
1395:
1392:(4): 830ā41.
1391:
1387:
1383:
1376:
1373:
1368:
1364:
1359:
1354:
1349:
1344:
1340:
1336:
1332:
1325:
1322:
1317:
1313:
1308:
1303:
1298:
1293:
1289:
1285:
1281:
1274:
1271:
1266:
1262:
1258:
1254:
1250:
1246:
1243:(1): 99ā106.
1242:
1238:
1231:
1228:
1223:
1219:
1214:
1209:
1205:
1201:
1197:
1190:
1187:
1182:
1178:
1173:
1168:
1164:
1160:
1156:
1149:
1146:
1141:
1137:
1132:
1127:
1123:
1119:
1115:
1111:
1107:
1100:
1098:
1094:
1089:
1085:
1080:
1075:
1071:
1067:
1063:
1056:
1053:
1047:
1044:
1039:
1035:
1030:
1025:
1021:
1017:
1013:
1009:
1005:
998:
995:
990:
986:
981:
976:
971:
966:
962:
958:
954:
947:
944:
939:
935:
930:
925:
921:
917:
913:
909:
905:
898:
895:
890:
886:
882:
878:
874:
870:
866:
859:
857:
853:
848:
844:
839:
834:
830:
826:
822:
818:
814:
807:
804:
799:
795:
790:
785:
781:
777:
773:
769:
765:
758:
755:
750:
746:
742:
738:
734:
730:
723:
720:
715:
711:
706:
701:
697:
693:
689:
685:
681:
674:
671:
666:
662:
658:
654:
651:(4): 341ā78.
650:
646:
639:
632:
629:
624:
620:
616:
612:
609:(1ā4): 1ā52.
608:
604:
600:
593:
590:
585:
581:
577:
573:
569:
565:
558:
555:
548:
546:
539:
537:
530:
528:
521:
519:
516:
511:
509:
505:
501:
497:
493:
489:
485:
481:
477:
473:
469:
456:
453:
449:
446:
443:
439:
434:
430:
427:
426:
422:
419:
417:
413:
408:
405:
402:
400:
396:
393:
390:
388:
384:
381:
378:
376:
372:
369:
366:
364:
360:
357:
354:
352:
348:
344:
340:
337:
334:
330:
325:
322:
318:
307:
304:
300:
297:
294:
290:
285:
281:
278:
277:
273:
270:
268:
264:
259:
256:
253:
251:
247:
244:
241:
239:
235:
232:
229:
227:
223:
220:
217:
215:
211:
208:
205:
203:
199:
195:
191:
188:
185:
181:
176:
173:
169:
158:
155:
151:
148:
145:
141:
136:
132:
129:
128:
124:
121:
119:
115:
110:
107:
104:
102:
98:
95:
92:
90:
86:
83:
80:
78:
74:
71:
68:
66:
62:
59:
56:
54:
50:
46:
42:
39:
36:
32:
27:
24:
20:
3709:
3697:M-CSFR/CSF1R
3684:heterodimer)
3670:heterodimer)
3599:Antagonists:
3598:
3570:
3549:
3528:
3488:
3467:
3440:Risankizumab
3421:
3411:
3389:
3379:
3362:NNC0114-0006
3357:NNC0114-0005
3353:
3338:
3316:
3296:
3275:
3250:
3204:
3169:
3143:
3126:Tralokinumab
3121:Lebrikizumab
3116:Anrukinzumab
3112:
3087:
3079:
3061:
3046:
3020:
2994:
2973:
2963:
2922:
2865:Clazakizumab
2856:
2841:
2820:
2804:Benralizumab
2800:
2791:Antagonists:
2790:
2780:
2763:Pascolizumab
2754:
2745:Antagonists:
2744:
2724:
2678:
2647:
2602:
2581:
2561:
2537:Antagonists:
2536:
2507:
2356:IL 17 family
1982:
1916:
1908:
1900:
1881:
1873:
1865:
1857:
1849:
1841:
1833:
1825:
1817:
1809:
1801:
1793:
1785:
1777:
1758:
1750:
1742:
1734:
1726:
1724:Fas receptor
1718:
1710:
1702:
1694:
1686:
1669:TNF receptor
1389:
1386:Cell Reports
1385:
1375:
1358:10261/123035
1338:
1334:
1324:
1287:
1283:
1273:
1240:
1236:
1230:
1206:(1): 522ā9.
1203:
1199:
1189:
1165:(1): 111ā9.
1162:
1158:
1148:
1116:(1): 38ā50.
1113:
1109:
1069:
1065:
1055:
1046:
1014:(51): ra17.
1011:
1007:
997:
960:
956:
946:
911:
907:
897:
872:
868:
820:
816:
806:
771:
767:
757:
735:(1): 79ā88.
732:
728:
722:
687:
683:
673:
648:
644:
631:
606:
602:
599:Banchereau J
597:Chomarat P,
592:
570:(3): 551ā7.
567:
563:
557:
543:
534:
525:
512:
492:Janus kinase
467:
465:
423:
345:IL4RA; CD124
342:Alt. symbols
274:
193:Alt. symbols
125:
44:Alt. symbols
3450:Ustekinumab
3430:Briakinumab
3422:Antibodies:
3393:Fezakinumab
3390:Antibodies:
3354:Antibodies:
3342:Denenicokin
3317:Antibodies:
3254:Iboctadekin
3233:Vunakizumab
3228:Secukinumab
3218:Perakizumab
3205:Antibodies:
3113:Antibodies:
3070:Ustekinumab
3065:Briakinumab
3062:Antibodies:
2974:Antibodies:
2900:Tocilizumab
2870:Elsilimomab
2857:Antibodies:
2809:Mepolizumab
2801:Antibodies:
2755:Antibodies:
2682:Daniplestim
2651:Basiliximab
2648:Antibodies:
2616:Celmoleukin
2611:Aldesleukin
2575:Lutikizumab
2570:Gevokizumab
2565:Canakinumab
2562:Antibodies:
1842:(TNFRSF13C)
1834:(TNFRSF13B)
1826:(TNFRSF12A)
1818:(TNFRSF11B)
1810:(TNFRSF11A)
1802:(TNFRSF10D)
1794:(TNFRSF10C)
1786:(TNFRSF10B)
1778:(TNFRSF10A)
906:. primary.
445:Swiss-model
327:Identifiers
296:Swiss-model
178:Identifiers
147:Swiss-model
29:Identifiers
3737:Categories
3505:B (IFN-Ī»3)
3501:A (IFN-Ī»2)
3435:Guselkumab
3425:Brazikumab
3320:Fletikumab
3223:Remtolumab
3213:Ixekizumab
3208:Brodalumab
3091:Binetrakin
3029:Oprelvekin
2998:Ilodecakin
2977:Enokizumab
2890:Siltuximab
2880:Olokizumab
2814:Reslizumab
2748:Pitrakinra
2728:Binetrakin
2697:Milodistim
2692:Leridistim
2661:Inolimomab
2636:Teceleukin
2555:Isunakinra
2492:modulators
1917:(TNFRSF27)
1909:(TNFRSF25)
1901:(TNFRSF21)
1882:(TNFRSF19)
1874:(TNFRSF18)
1866:(TNFRSF17)
1858:(TNFRSF16)
1850:(TNFRSF14)
1735:(TNFRSF6B)
1695:(TNFRSF1B)
1687:(TNFRSF1A)
875:: 701ā38.
867:. review.
817:Oncotarget
768:Oncotarget
549:References
474:, binding
441:Structures
436:Search for
425:p12.1-11.2
410:Other data
292:Structures
287:Search for
261:Other data
143:Structures
138:Search for
112:Other data
3710:Unsorted:
3571:Agonists:
3550:Agonists:
3529:Agonists:
3489:Agonists:
3468:Agonists:
3412:Agonists:
3380:Agonists:
3339:Agonists:
3297:Agonists:
3269:Tadekinig
3251:Agonists:
3170:Agonists:
3144:Agonists:
3088:Agonists:
3047:Agonists:
3021:Agonists:
2995:Agonists:
2964:Agonists:
2923:Agonists:
2905:Levilimab
2895:Sirukumab
2885:Sarilumab
2842:Agonists:
2781:Agonists:
2758:Dupilumab
2725:Agonists:
2702:Muplestim
2679:Agonists:
2603:Agonists:
2530:Pifonakin
2525:Mobenakin
2508:Agonists:
2201:prolactin
1759:(TNFRSF9)
1751:(TNFRSF8)
1743:(TNFRSF7)
1727:(TNFRSF6)
1719:(TNFRSF5)
1711:(TNFRSF4)
1703:(TNFRSF3)
1290:(1): 16.
392:NM_000418
351:NCBI gene
276:q13.1-q28
243:NM_000640
202:NCBI gene
94:NM_001560
53:NCBI gene
3664:IL-22RĪ±1
3630:instead.
2947:instead.
2875:mAb 1339
2860:ARGX-109
2824:TPI ASM8
2794:YM-90709
2545:Anakinra
2540:AF-12198
2430:TGF-beta
1931:JAK-STAT
1879:TAJ/TROY
1416:23972995
1367:25896327
1316:24143891
1265:38397076
1257:16327802
1222:18097054
1181:24879793
1140:26187331
1110:Cytokine
1088:15187136
1038:19109239
989:29930549
889:10358772
847:27351230
798:26418721
749:26088753
729:Cytokine
714:24723564
665:26689873
522:Function
455:InterPro
306:InterPro
157:InterPro
3682:IL-10RĪ²
3678:IL-20RĪ±
3668:IL-20RĪ²
3602:IL-36RA
3147:ALT-803
2426:Ser/Thr
2248:IL22RA2
2244:IL22RA1
2215:Type II
2144:IL12RB2
2140:IL12RB1
2123:IL12RB1
2022:Ī²-chain
1991:IL13RA2
1987:IL13RA1
1949:Ī³-chain
1407:3988532
1307:4016099
1131:4546937
1029:2739727
980:6001902
963:: 888.
938:9856949
916:Bibcode
908:Science
838:5226507
789:4741738
705:4165413
623:9914942
584:9852261
515:IL13RA2
508:eotaxin
480:IL13RA1
451:Domains
421:Chr. 16
399:UniProt
302:Domains
250:UniProt
187:IL13RA2
153:Domains
101:UniProt
38:IL13RA1
3638:Others
3611:Others
3563:IL1RL2
3542:IL1RL1
3279:IL18BP
2550:IL-1RA
2445:family
2440:TGFBR2
2435:TGFBR1
2389:IL17RE
2384:IL17RD
2379:IL17RC
2374:IL17RB
2369:IL17RA
2346:IL18R1
2299:IFNGR2
2295:IFNGR1
2286:IFNAR2
2282:IFNAR1
2261:IL20RB
2257:IL20RA
2236:IL10RB
2232:IL10RA
2166:other
2096:IL27RA
2087:IL11RA
2055:GM-CSF
1940:Type I
1823:TweakR
1655:CMKLR1
1633:CX3CR1
1439:(MeSH)
1414:
1404:
1365:
1314:
1304:
1263:
1255:
1220:
1179:
1138:
1128:
1086:
1036:
1026:
987:
977:
936:
887:
845:
835:
796:
786:
747:
712:
702:
663:
621:
582:
404:Q9H186
387:RefSeq
380:147781
332:Symbol
272:Chr. X
255:Q14627
238:RefSeq
231:300130
183:Symbol
123:Chr. X
106:P78552
89:RefSeq
82:300119
34:Symbol
3521:IL-31
3481:IL-28
3460:IL-27
3404:IL-23
3372:IL-22
3331:IL-21
3289:IL-20
3243:IL-18
3162:IL-17
3136:IL-15
3080:IL-13
3039:IL-12
3013:IL-11
2987:IL-10
2414:CSF1R
2342:IL18R
2335:IL1R2
2330:IL1R1
2266:IL28R
2253:IL20R
2240:IL22R
2228:IL10R
2178:G-CSF
2160:Other
2149:IL23R
2136:IL12R
2113:CNTFR
2078:IL6RA
2065:gp130
2048:IL5RA
2039:IL3RA
2010:IL21R
2000:IL7RA
1983:IL13R
1974:IL15R
1970:IL2RB
1966:IL2RA
1914:EDA2R
1891:21-27
1839:BAFFR
1768:11-20
1756:CD137
1708:CD134
1692:TNFR2
1684:TNFR1
1650:CCBP2
1629:CX3C
1623:Other
1614:CXCR7
1609:CXCR6
1604:CXCR5
1599:CXCR4
1594:CXCR3
1587:CXCR2
1582:CXCR1
1559:CCR10
1519:CCRL2
1509:CCRL1
1487:GPCRs
1261:S2CID
641:(PDF)
504:STAT6
470:is a
416:Locus
267:Locus
118:Locus
3628:here
3626:See
2956:IL-9
2945:here
2936:IL-8
2915:IL-7
2834:IL-6
2773:IL-5
2717:IL-4
2671:IL-3
2595:IL-2
2500:IL-1
2364:IL17
2278:-Ī±/Ī²
2108:LIFR
2103:OSMR
2044:IL5R
2035:IL3R
2005:IL9R
1996:IL7R
1979:IL4R
1962:IL2R
1871:GITR
1863:BCMA
1855:NGFR
1847:HVEM
1831:TACI
1807:RANK
1799:DcR2
1791:DcR1
1748:CD30
1740:CD27
1732:DcR3
1716:CD40
1700:LTBR
1677:1-10
1643:XCR1
1577:IL-8
1554:CCR9
1549:CCR8
1544:CCR7
1539:CCR6
1534:CCR5
1529:CCR4
1524:CCR3
1514:CCR2
1505:CCR1
1412:PMID
1363:PMID
1312:PMID
1253:PMID
1218:PMID
1177:PMID
1136:PMID
1084:PMID
1034:PMID
985:PMID
934:PMID
885:PMID
843:PMID
794:PMID
745:PMID
710:PMID
661:PMID
619:PMID
580:PMID
496:STAT
488:IL-4
484:IL4R
482:and
466:The
375:OMIM
368:6015
363:HGNC
356:3566
336:IL4R
226:OMIM
219:5975
214:HGNC
207:3598
77:OMIM
70:5974
65:HGNC
58:3597
3654:CD4
3619:JAK
2419:KIT
2409:Tyr
2325:IL1
2173:EPO
1906:DR3
1898:DR6
1783:DR5
1775:DR4
1639:XC
1569:CXC
1402:PMC
1394:doi
1353:hdl
1343:doi
1302:PMC
1292:doi
1245:doi
1208:doi
1204:180
1167:doi
1163:193
1126:PMC
1118:doi
1074:doi
1070:172
1024:PMC
1016:doi
975:PMC
965:doi
924:doi
912:282
877:doi
833:PMC
825:doi
784:PMC
776:doi
737:doi
700:PMC
692:doi
653:doi
611:doi
572:doi
510:.
502:of
127:q24
3739::
3584:,
3580:,
3503:,
3195:,
3191:,
3187:,
3183:,
3179:,
2517:,
2428::
2344:/
2297:/
2291:-Ī³
2280:/
2259:/
2255:/
2246:/
2242:/
2238:/
2234:/
2230:/
2196:GH
2194::
2092:27
2083:11
2046:/
2037:/
1998:/
1989:/
1985:/
1981:/
1972:/
1964:/
1507:/
1497:CC
1410:.
1400:.
1388:.
1384:.
1361:.
1351:.
1339:75
1337:.
1333:.
1310:.
1300:.
1286:.
1282:.
1259:.
1251:.
1241:12
1239:.
1216:.
1202:.
1198:.
1175:.
1161:.
1157:.
1134:.
1124:.
1114:75
1112:.
1108:.
1096:^
1082:.
1068:.
1064:.
1032:.
1022:.
1010:.
1006:.
983:.
973:.
959:.
955:.
932:.
922:.
910:.
883:.
873:17
871:.
855:^
841:.
831:.
819:.
815:.
792:.
782:.
770:.
766:.
743:.
733:75
731:.
708:.
698:.
688:16
686:.
682:.
659:.
649:62
647:.
643:.
617:.
607:17
605:.
578:.
566:.
3699:)
3680:/
3666:/
3656:)
3588:)
3586:Ī³
3582:Ī²
3578:Ī±
3576:(
3507:)
3499:(
3199:)
3197:F
3189:D
3185:C
3181:B
3177:A
3175:(
2521:)
2519:Ī²
2515:Ī±
2513:(
2481:e
2474:t
2467:v
2293:/
2284:/
2142:/
2138:/
2094:/
2085:/
1968:/
1489:)
1485:(
1466:e
1459:t
1452:v
1418:.
1396::
1390:4
1369:.
1355::
1345::
1318:.
1294::
1288:2
1267:.
1247::
1224:.
1210::
1183:.
1169::
1142:.
1120::
1090:.
1076::
1040:.
1018::
1012:1
991:.
967::
961:9
940:.
926::
918::
891:.
879::
849:.
827::
821:7
800:.
778::
772:6
751:.
739::
716:.
694::
667:.
655::
625:.
613::
586:.
574::
568:1
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.